DEFA14A: Silexion Adjourns Meeting, Seeks Capital Boost for Nasdaq

Silexion Therapeutics Corp. adjourned its extraordinary general meeting to August 19, 2025, to vote on increasing authorized share capital to meet Nasdaq listing requirements and enable future equity raises.

Summary

• The Extraordinary General Meeting (EGM) of Silexion Therapeutics Corp. was convened on August 12, 2025, and subsequently adjourned for one week without conducting any business.
• The EGM will reconvene on August 19, 2025, at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time at Meitar Law Offices.
• The primary purpose of the EGM is to approve a proposal to increase the company's authorized share capital from US$20,000 (1,481,482 ordinary shares of US$0.0135 par value each) to US$121,500 (9,000,000 ordinary shares of US$0.0135 par value each).
• This increase is crucial for Silexion to achieve and maintain compliance with Nasdaq Listing Rule 5550(b)(1), which mandates at least $2.5 million of shareholders' equity.
• The initial deadline for Silexion to achieve this shareholders' equity level and remain listed on Nasdaq is September 19, 2025.
• The company intends to issue equity securities through value-enhancing transactions as the primary method to augment its shareholders' equity.
• The record date for the Extraordinary Meeting remains the close of business on July 24, 2025.

Sentiment

Score: 4

Explanation: While the company is proactively addressing a critical Nasdaq compliance issue, the immediate need for an emergency meeting and its adjournment suggest underlying challenges. The proposed solution involves significant potential dilution through future equity raises, which could impact existing shareholders. The underlying biotech pipeline has positive aspects, but the immediate financial/governance news presents a concern.

Positives

• The company is proactively addressing its Nasdaq listing compliance issues by seeking to increase authorized share capital.
• The proposed increase in authorized share capital provides the necessary flexibility for future equity raises, which can strengthen the company's balance sheet.
• Silexion Therapeutics is a clinical-stage oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies for solid tumors driven by KRAS mutations.
• Their first-generation product, LODER, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer.
• The company is advancing its next-generation siRNA candidate, SIL204, which targets a broader range of KRAS mutations and shows significant potential in preclinical studies.

Negatives

• Silexion is currently not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in shareholders' equity.
• The necessity for an extraordinary general meeting and a substantial increase in authorized shares indicates a pressing need for capital and financial restructuring.
• The adjournment of the meeting suggests potential challenges in securing sufficient shareholder votes or achieving a quorum for the critical proposal.

Risks

• Risk of Silexion's inability to maintain its Nasdaq listing and restore compliance with all Nasdaq Listing Rules.
• Uncertainty regarding Silexion's future capital requirements and its ability to obtain additional capital through equity issuances or other means.
• Potential impact of the regulatory environment and compliance complexities on the company's operations and financial standing.
• Other risks and uncertainties detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025.

Future Outlook

Silexion aims to achieve and maintain compliance with Nasdaq Listing Rule 5550(b)(1) by increasing its authorized share capital and subsequently effecting additional transactions to augment its shareholders' equity. The company anticipates that the issuance of equity securities through value-enhancing transactions will be the primary method to reach and sustain the required $2.5 million shareholders' equity minimum.

Management Comments

• "The primary rationale for the proposed increase in authorized share capital is to provide sufficient authorized share capital so as to enable Silexion to achieve and maintain compliance with Nasdaq Listing Rule 5550(b)(1)."
• "The Company faces an initial deadline of September 19, 2025 for achieving that shareholders equity level for its securities to remain listed on Nasdaq, and must furthermore effect additional transactions thereafter that augment its shareholders equity, in keeping with that $2.5 million minimum."
• "The Companys issuance of equity securities in value-enhancing transactions, whether extraordinary or ordinary-course, will serve as the primary means by which it can effectively achieve that goal, and for that, it will need additional authorized share capital."

Industry Context

Biotechnology companies, particularly those in the clinical-stage, are highly capital-intensive and frequently rely on capital markets for funding research, development, and clinical trials. Maintaining a Nasdaq listing is critical for access to capital and investor visibility. Non-compliance with listing rules, such as minimum shareholders' equity, is a common challenge for smaller or developing companies, often necessitating strategic financial maneuvers like share capital increases to facilitate future funding rounds and ensure continued market access.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential significant dilution from future equity issuances required to raise capital. Their vote on the authorized share capital increase is critical for the company's continued Nasdaq listing.
• Nasdaq: Requires Silexion to comply with its listing rules, specifically the $2.5 million shareholders' equity minimum, by September 19, 2025.
• Employees: Their continued employment and the company's operational stability are dependent on the successful resolution of the Nasdaq compliance issue and subsequent capital raising.
• Creditors: The company's financial health and ability to meet its obligations could be positively impacted by successful capital raises, or negatively impacted if compliance is not achieved.

Next Steps

• Shareholders are urged to submit or change their proxies for the reconvened Extraordinary Meeting.
• The Extraordinary General Meeting will reconvene on August 19, 2025, for shareholders to vote on the proposal to increase authorized share capital.
• Silexion must achieve $2.5 million in shareholders' equity by September 19, 2025, to comply with Nasdaq Listing Rule 5550(b)(1).
• The company plans to effect additional transactions, including the issuance of equity securities, to augment its shareholders' equity.

Key Dates

Recommendation

Silexion Therapeutics is at a critical juncture, actively working to resolve a Nasdaq listing compliance issue by proposing a significant increase in authorized share capital. While this proactive step is necessary to maintain its listing and facilitate future capital raises, it signals an immediate need for funding and the likelihood of substantial shareholder dilution. The company's clinical-stage oncology pipeline (LODER, SIL204) holds long-term potential, but the short-term focus is on corporate finance and governance. Investors should hold to observe the outcome of the reconvened Extraordinary Meeting and the subsequent capital raising activities, as these events will significantly influence the company's financial stability and future trajectory. The risk of delisting and the certainty of dilution warrant caution, balancing the long-term potential with immediate operational challenges.

Keywords

Silexion Therapeutics, SLXN, Nasdaq, Share Capital, Equity Compliance, Proxy Statement, Shareholder Meeting, Capital Raise, RNAi, Oncology, Biotechnology, KRAS, Pancreatic Cancer